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Purpose: To evaluate bone density changes at the level of normal bone and bone metastases after
zoledronic acid (ZA) treatment in oncologic patients.
Materials and methods: We retrospectively evaluated 72 consecutive adult patients with histologi-
cally conﬁrmed solid tumors with at least 1 newly diagnosed bone metastatic lesion. Bone metastases
were diagnosed by bone scans and conﬁrmed with computed tomography (CT). Patients received
intravenous ZA, 4 mg, by 15-min infusion every 28 day through a peripheral or a central venous access
and were monitored for at least 3 months and a maximum of 24 months. Bone density was determined
at the level of bone metastases and at the level of normal trabecular and cortical bone using a ROI-
based approach.
Results: A signiﬁcant increase was demonstrated at the level of normal trabecular bone of the
calvarium and the femoral neck. No signiﬁcant increase of density was observed at the level of the
normal cortical bone. Bone metastases showed a signiﬁcant increase in CT density as compared to
baseline up to 24 months after zoledronic acid.
Conclusion: We have found that long term treatment with ZA increases trabecular bone density in
oncologic patients whereas normal cortical bone changes are not detectable.
& 2012 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Patients with advanced breast, prostate, lung and colo-rectal
cancer frequently develop bone metastases (BMs). These lesions
may be asymptomatic or may cause pain, pathologic fractures,
malignant hypercalcemia, epidural spinal cord compression and/
or shorten survival [1]. The underlying pathophysiology of BMs
involves reciprocal interactions between tumor cells and the bone
micro-environment that lead to the disruption of the balanced
physiological activity between osteoblasts and osteoclasts. Loss of
this critical balance results in a spectrum of osteolytic to osteo-
blastic bone lesions [2].
Computed tomography (CT) provides accurate morphological
images of bone, allowing visualization of cortical and trabecular
bone, tumor margins and dimensions [2]. Anatomical extension of
lesions is depicted on CT studies as well as the presence of. This is an open access article un
Quattrocchi).sclerosis in the context of lytic lesions [3]. Whole-body CT scans
are diffusely used to detect osteolytic, mixed or osteoblastic bone
lesions in the staging, follow-up and re-staging studies of onco-
logical patients. CT scans are also considered crucial in the
assessment of the bone response to therapy [2,4,5]. In osteolytic
bone metastases, indeed, an increase of density is considered an
indicator of response to therapy [2].
As potent inhibitors of osteoclast function, biphosphonates are
being incorporated into the management of metastatic bone
disease [6], with beneﬁcial effects on skeletal complications
[7,9], bone pain [9], quality of life [7–9], particularly in advanced
breast cancer [7,10], multiple myeloma [8,11], and more recently
in lung, prostate and kidney cancer [12,13]. Zoledronic acid (ZA) is
a potent third generation nitrogen-containing biphosphonate,
which has been widely used in the treatment of Paget’s disease
of bone [14], hypercalcemia [15], multiple myeloma [16], breast
cancer BMs [16], prostate cancer BMs [17], lung cancer BMs [18]
and osteolytic BMs [19,20].
In patients with BMs, decrease of bone density is the conse-
quence of several factors, not only of pathologic mechanisms atder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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concurrent postmenopausal or drug-related osteoporosis, or of
androgen-deprivation therapy in men with prostate cancer [21].
In multicenter randomized controlled trials, once yearly injec-
tion of 5 mg of ZA has been demonstrated to signiﬁcantly reduce
the risk of vertebral and hip fractures in postmenopausal women
[22] and the risk of recurrence of clinical fractures in men and
women with a recent hip fracture [23].
Sclerosis of bone metastases has been documented by CT
imaging after ZA treatment in studies [24–26] conducted on
patients at an advanced stage of cancer. However, the CT changes
of the normal bone after ZA treatment in oncological patients has
not yet been established.
The primary aim of this study was to determine CT density
changes of the normal trabecular and cortical bone tissue in
oncological patients undergoing routine whole body CT examina-
tions; as reference, in the same group of patients, the rate of
sclerosis of bone metastases up to 24 months after the initiation
of ZA treatment was evaluated.2. Materials and methods
2.1. Patients
We conducted a retrospective analysis of adult patients with
histologically conﬁrmed solid tumors with at least 1 newly
diagnosed bone metastatic lesion. Bone metastases were diag-
nosed by bone scans and conﬁrmed on CT images. The study was
carried out according to the principles of the Declaration of
Helsinki. Our institutional review board approved the study and
all patients provided a written informed consent to receive ZA
administration and to undergo CT examinations.
The patients underwent therapy with ZA (Zometas, Novartis
Pharma, USA) in the period between December 2004 and Febru-
ary 2010. We included patients with a total bilirubin level lower
than 2 mg/dL, and serum creatinine level lower than 2 mg/dL, to
avoid the effects of prolonged immobility and hepatic or renal
osteodystrophy on bone metabolism. Patients with proven peptic
ulcer, poor performance status unrelated to bone disease (WHO
374), Paget’s disease, primary hyperparathyroidism, administra-
tion of calcitonin and any prior treatment with bisphosphonates
were excluded from the study.
Concurrent cytotoxic, hormonal or steroid therapy was permitted.
Each patient was treated with chemotherapy and/or radiotherapy,
using an individualized therapeutic approach according to the
current international recommendations and the institutions’ practice.
Patients with metastatic breast cancer were allowed to receive
hormonal therapy with tamoxifen or aromatase inhibitors in case
of estrogen and/or progesterone receptor positive disease. Patients
with castration-sensitive metastatic prostate cancer as well as
patients with castration refractory disease were allowed to continue
androgen deprivation therapy with luteinizing hormone-releasing
hormone (LHRH) analogs and/or anti-androgens. Patients received
intravenous ZA, 4 mg, by 15-min infusion every 28 day through a
peripheral or a central venous access and were monitored for at least
3 months and a maximum of 24 months. According to standard
procedures, supplementation with vitamin D (400 Units/die) and
calcium (500mg/die) was added.
All patients were monitored for skeletal related events (SREs)
by physical examination and by diagnostic imaging techniques
(X-rays, CT scan, or magnetic resonance imaging scan) at any
symptom or sign indicating skeletal disease progression. The
deﬁnition of SRE included pathologic fractures, surgery or radio-
therapy to bone to treat or prevent an impending fracture,
palliative radiotherapy to bone, spinal cord compression,malignant hypercalcemia, and changes in antineoplastic therapy
because of worsening bone pain.
2.2. CT scans
CT images were obtained using a 16 and a 64 slice CT scanner
(Somatom Sensation, Siemens, Erlangen, Germany). Whole body
CT scans were acquired at baseline (prior to treatment) and every
3 and/or 6 and/or 12 months, according to the staging and
restaging needs of each patient, to the current international
recommendations and to the institutions’ practice. WBCT used
for the analysis were performed up to 24 months after the
initiation of treatment with ZA. Images were obtained using the
whole body protocol (KV 120, 140 mAs, B30 kernel) and were
reformatted at 5 mm section thickness, before and after bolus
administration of non-ionic iodinated contrast agent, at the
concentration of 350 mg/mL (Iobitridol, Xenetixs, Guerbet,
France), injected intravenously with a power injector (EnVision;
Medrad Italia, PV, Italy) (total volume¼120 mL, ﬂow¼3 mL/min).
Image evaluation was conducted on a separate workstation
applying bone-speciﬁc Hounsﬁeld Units (HU) windows (width:
2500 HU; window level: 480 HU). By using a two-reader consensus,
C.C.Q. and P.D. drew regions of interest (ROIs) on images obtained in
the contrast-enhanced scan (60–70 s after contrast injection). After
opening the CT scans on the eFilm workstation (MERGE-Healthcare,
NL), images were anonymized with no access to the date of the
examination. ROIs were chosen at the level of the bone metastases on
the basis of concordant CT and bone scans at baseline. Bone lesions
previously treated by radiotherapy were not considered for analysis.
ROIs were drawn at the level of normal trabecular and cortical
bone in the occipital calvarial bone chosen as a non-weight-bearing,
and in the left femoral neck chosen as a weight-bearing skeletal
segment. At the level of the normal trabecular bone of the left femoral
neck, negative values related to the high content of fatty bone marrow
were not considered for analysis and alternative ROIs were drawn.
At each site, three circle-sized ROIs (0.1 cm2 for bone metas-
tases and normal trabecular bone and 0.05 cm2 for normal cortical
bone) were drawn on an eFilm workstation (MERGE-Healthcare,
NL) and the average value was used for analysis (Fig. 1). Since
mixed bone metastases are frequent in patients with advanced
cancer, two groups of predominantly lytic or predominantly
sclerotic metastases were classiﬁed according to an attenuation
threshold value of 300 HU, as previously reported [27]. Measure-
ments were obtained at baseline CT and at the CT scans performed
12 and 24 months after the initiation of ZA treatment.
2.3. Statistical analysis
Patient demographic data, clinical data, primary tumor charac-
teristics and CT density measurements were loaded on a database.
The absolute data were plotted and the relative increments to
baseline were calculated.
Descriptive statistics (median, quartiles, ranges, average and
standard deviation) was performed. The difference between groups
was determined using the non-parametric Wilcoxon signed ranks
test on the SPSS platform (SPSS, 14.0). The p¼0.05 was considered
as the threshold for a signiﬁcant difference among groups.3. Results
3.1. Patients
We included 72 consecutive patients (35 males and 37
females). The mean age at the diagnosis of bone metastases was
67712 (7standard deviation) years. Demographic details are
Table 1
Patients demographics and characteristics.
Total Breast ca. Prostate ca. Colon ca. Lung ca. Other
Patients no. 72 29 14 10 6 13
M/F 35/37 1/28 14/0 8/2 5/1 7/6
Age (years) 67712 66712 7378 7679 68711 58713
Histotype – Ductal ca. 23 Adenoca. 14 Adenoca. 9 Adenoca. 2
Inﬁltrative lobular ca. 6 Undifferentiated ca. 1 Small cell ca. 2
Squamous cell ca. 2
No. of patients with lytic/blastic metastases at baseline 46/26 21/8 6/8 7/3 4/2 8/5
Fig. 1. Regions of interest (ROIs) (red spots) were drawn at the level of the trabecular and cortical occipital calvarium (A), trabecular and cortical left femoral neck (B) and
in the context of bone metastatic lesions (C). Average of three values at each site was used for comparison between groups. (For interpretation of the references to color in
this ﬁgure legend, the reader is referred to the web version of this article.)
Table 2
CT density values and increments of normal bone at baseline, 12 months and
24 months after ﬁrst administration of ZA.
No. of
observations
HUs median
[25–75%]
Average of
increment vs.
baseline
[7SEM]
p value
[vs. baseline]
Calvarial cortical bone
0 55 1536 [1327–1762] – –
12 months 55 1554 [1316–1906] 14% [78%] 0.05
24 months 37 1591 [1298–1954] 22 [715%] 0.11
Calvarial trabecular bone
0 55 1056 [878–1234] – –
12 months 55 1138 [890–1338] 8 [73%] 0.01
24 months 37 1146 [961–1506] 11 [74%] 0.02
Femoral cortical bone
0 57 726 [586–844] – –
12 months 57 715 [617–830] 12% [710%] 0.21
24 months 37 671 [587–846] 5% [74%] 0.43
Femoral trabecular bone
0 57 120 [89–153] – –
12 months 57 137 [00–179] 23% [714%] 0.09
24 months 37 137 [100–173] 18% [76%] 0.005
C.C. Quattrocchi et al. / Journal of Bone Oncology 1 (2012) 24–2926provided in Table 1. According to the CT density threshold of
300 HUs, 64% (46/72) of the patients were included in the group
of osteolytic metastases and 36% (26/72) of the patients were
included in the group of osteoblastic metastases.
The largest group was represented by patients with a diagnosis
of breast cancer and a high prevalence of osteolytic metastases
(72%, 21/29) at baseline.
An acute reaction after the ﬁrst administration of ZA was
observed in 7% of the cases (5/72); episodes of asymptomatic
hypocalcemia in 9% of the cases (6/72); a slight increase of
creatinine serum levels (inferior to 1.5 mg/dL) in 11% of the cases
(8/72), osteonecrosis of the mandible in 3% of the cases (2/72).
Skeletal related events were not observed in 50% of the cases
(36/72). Among the group of patients that experienced a skeletal
related event, 30 patients underwent radiotherapy, 4 patients
experienced bone fractures and 2 patients received orthopedic
surgery. No atypical fractures were reported.
3.2. CT density of normal bone
Among the 72 patients included in the study, density mea-
surements were available at baseline in a group of 55 patients for
the occipital calvarium and a group of 57 patients for the left
femoral neck, because of the presence of metastatic lesions,
suspicious focal areas of altered density, or the presence of
prosthesis at these sites. Details are presented in Table 2.
After 12 months and 24 months of ZA treatment, we observed
a signiﬁcant increase of density at the level of normal trabecular
bone of the occipital calvarium, as compared to baseline (po0.05)
(Fig. 2). The average increment of bone density was higher at the
level of the left femoral neck as compared to the occipital
calvarium. However, the increase of density at the femoral neck
reached the signiﬁcance threshold only after 24 months since the
initiation of ZA treatment (po0.001) (Fig. 2).
At the level of the normal cortical bone, we did not observe
signiﬁcant increases of density both in the occipital calvarium and
in the left femoral neck (Table 2).3.3. CT density of bone metastases
CT density at the level of BMs increased during treatment
(Table 3 and Fig. 3). Patients showed an average increment of 98%
after 12 months of treatment. Density values were 1.75 times
higher than baseline after 24 months of treatment. As shown in
Table 2, the relative increment of density was higher for osteolytic
metastases (1.34 times at 12 months and 2.56 times at 24
months) than for osteoblastic metastases (35% at 12 months
and 31% at 24 months). The density of bone osteolytic metastases
signiﬁcantly increased at 24 months in comparison to the 12
months time point (Fig. 4).
Fig. 2. Box plots represent median, quartiles, minimum and maximum values of
absolute Hounsﬁeld units of calvarium (A and C) and femoral (D and E) normal
bone. NCB¼normal cortical bone; NTB¼normal trabecular bone.
Table 3
CT density values and increments of bone metastatic lesions at 12 months and
24 months after ﬁrst administration of ZA. HU¼Hounsﬁeld units; SEM¼standard
error of the mean; BMs¼bone metastases.
No. of
observations
HUs median
[25–75%]
Average of
increment vs.
baseline
[7SEM]
p value
[vs. baseline]
Total patients
0 72 260 [154–466] – –
12 months 54 525 [323–725] 98% [720%] o0.0001
24 months 35 555 [413–712] X1.75 [737%] o0.0001
Patients with lytic BMs
0 46 185 [103–251] – –
12 months 34 371 [222–541] X1.34 [727%] o0.0001
24 months 23 554 [348–617] X2.56 [740%] o0.0001
Patients with blastic BMs
0 26 514 [463–779] – –
12 months 20 747 [611–1007] 35% [76%] 0.001
24 months 11 774 [588–1096] 31% [77%] 0.03
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We found that long-term treatment with ZA increases trabe-
cular bone density in oncologic patients, whereas normal cortical
bone changes are not detectable. These ﬁndings may have
important implications in tumor treatment and in the manage-
ment of osteoporotic patients who are treated with much lower
doses of ZA.
Biphosphonates are known to reduce the incidence of skeletal
complications in patients with BMs and delay the onset of SREs
and the progression of skeletal disease. ZA is a third generation
bisphosphonate that has been shown to be more effective than
other biphosphonates [27] and signiﬁcantly reduces skeletal
related complications compared with placebo in patients with
BMs [28].
This study shows increase of bone density at the level of the
normal trabecular bone in oncologic patients. In non-oncologicpostmenopausal osteoporotic patients, once yearly injections of
ZA (5 mg/year vs. much higher doses in oncology) signiﬁcantly
increase bone mineral density (BMD) of the trabecular compart-
ment at the spine, femoral neck, trochanter and hip, when
compared with placebo, as measured by both dual-energy X-ray
absorptiometry (DXA) and quantitative computed analysis (QCT)
[29].
In oncologic patients with bone metastases, bone resorption
may be linked to several factors such as the normal ageing
process, concurrent postmenopausal or drug-related osteoporosis,
androgen-deprivation therapy in men with prostate cancer; in our
group, even in the occurrence of these phenomena, we still
observed an increase of bone density after 12 months (occipital
calvarium) and 24 months (occipital calvarium and left femoral
neck) of ZA treatment.
We observed a different response to ZA treatment over time:
the results were different at the femoral neck as compared to the
calvarium. Normal trabecular bone showed a signiﬁcant increase
after 12 months of ZA treatment at femoral neck but not at the
calvarium. This could be explained either by a different effect of
ZA in different skeletal segments or, alternatively, by concomitant
higher bone turnover of the trabecular femoral neck.
At the 24 months time-point, the increase of density of the
femoral neck showed a higher increase rate as compared to the
calvarium: we interpreted these results possibly as a slow but
progressive effect of weight-bearing at the femoral neck.
Density measures of the cortical bone did not yield, in respect
to a trend toward a density increase, a signiﬁcant change up to 24
months: still, these results may be explained by a different effect
of ZA on the cortical bone in comparison to that on the trabecular
bone or by HU measurements at a saturation level in the cortical
compartment, so that slight increases could not be detected.
These results, thus, conﬁrm previous reports of a slight but not
signiﬁcant increase of cortical density after ZA treatment [29].
We, moreover, conﬁrmed previous evidence of a net increase
of CT density of bone metastases after ZA treatment and demon-
strated that the changes persist at a 24 months follow-up. This
study and previous reports [24–26] have demonstrated signiﬁ-
cant sclerotic changes of BMs, more evident in patients with
osteolytic lesions. The current data show that changes persist
after 24 months of treatment in both osteolytic and osteoblastic
metastases. The CT density of osteolytic metastases shows a
progressive increase at 24 months in comparison to the 12
months time-point, suggesting that the effect does not reach a
plateau level, even after 24 months of treatment. These data
support and conﬁrm a dominant effect of ZA as an inhibitor of
osteoclastic activity, even in the long-term treatment. Previous
reports have shown the effect of concomitant ZA and radiation
treatment on density of bone metastases [30]. Radiation therapy
alone has been previously shown to increase density of bone
metastases by means of quantitative computed tomography
[31–33]; in our study, however, skeletal segments previously
treated with radiation were not considered and excluded from
analysis.
Since concurrent antiblastic and/or hormonal treatments were
not discontinued, we cannot rule out an effect on density due to
other drugs or to their interactions with ZA. However, bone
density increase was seen both in extra-skeletal ‘‘responder’’
and ‘‘non-responder’’ patients, as previously shown [25]. In rat
models, ZA alone produces dose-dependent increases in cancel-
lous bone volume and connectivity, 100 times more effectively
than pamidronate, and decreases bone resorption [34]. As such,
due to the inclusion of patients with different primary tumors and
different chemotherapeutic schedules, it is sufﬁciently safe to
claim, on the basis of our and previous reported data, a direct and
independent effect of ZA on the increase of density of bone
Fig. 4. Box plots represent median, quartiles, minimal and maximal values of absolute Hounsﬁeld units of all (A), predominantly lytic (B) and predominantly blastic (C)
bone metastases measured at baseline, 12 months and 24 months after initiation of ZA treatment.
Fig. 3. (A–C) A 65-year-old woman with diagnosis of ductal breast carcinoma. CT images of a predominantly lytic lesion (arrow in A) observed at baseline (A), 12 months
(B) and 24 months (C) after initiation of ZA treatment; (D, E) A 75-year-old man with diagnosis of prostate adenocarcinoma. CT images of a predominantly blastic lesion
(arrow in D) observed at baseline (D), 12 months (E) and 24 months (F) after initiation of ZA treatment.
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reports showing that biphosphonate administration may signiﬁ-
cantly decrease levels of osteolytic [35,36] and osteoblastic
[37,38] bone markers. Moreover, up-regulation of NF-kB ligand
(RANKL) and osteoprotegerin levels [39], critical for the regulation
of osteoclasts maturation, function, and survival, are known to
occur following biphosphonates treatment [40,41].
Osteosclerosis was also signiﬁcant at the level of osteoblastic
bone metastases. The effect, in this case, seemed to reach a
plateau level since the difference between the 24 and the 12
months time point was not signiﬁcant in this subgroup. Residual
osteoclastic activity is present even in sclerotic metastases as it is
suggested by some evidence of increased bone resorption in
osteosclerotic metastases of prostate cancer [42,43]. Yi et al.
[44] have shown in an animal model of osteoblastic metastases
that an initial phase of bone destruction is followed by extensive
formation of bone. Their data suggest that bone resorption
precedes bone formation in the development of osteoblastic
metastases and that osteoclast activation plays an important role
even in the course of osteoblastic metastases [44,45]. The plateau
of the increment of density, indeed, could be explained either by a
minor effect of ZA on osteoblastic metastases or even by the
reaching of HU saturation levels.A limitation of the study is represented by the lack of
quantitative computed tomography measurements [29]. More-
over, given the thin thickness of the cortical bone at the femoral
neck, analysis at this site may be biased. However, on this regard,
our method of analysis can be applied on routine CT images to
evaluate responses to ZA therapy in oncologic patients without
needs of additional softwares or phantoms. As such, measure-
ments of response to therapy may be conducted in the standard
clinical setting without additional tools.
In conclusion, these results suggest that long-term treatment
with ZA increases the bone density both at the level of the normal
bone and at the level of bone metastases, with a potential effect
on reduction of the incidence of SRE in oncologic patients.References
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